Patient Identification
![](https://d1edr79mp9g5zc.cloudfront.net/5eb0affe-1991-449b-bfc0-a5a0516548bf/51d14fa8-e822-4aec-95b9-28b2c54ff375/51d14fa8-e822-4aec-95b9-28b2c54ff375_source__v.png)
Which Patients May Benefit from Protected PCI?
Impella® heart pumps may provide safe and effective hemodynamic support in elective and urgent high-risk PCI for a broad range of patients with complex coronary artery disease, hemodynamic compromise and comorbidities.
Patients benefit from this minimally invasive option that may:
- Enable more complete revascularization1
- Reduce symptoms and class of heart failure2 and improve LVEF1
- Significantly reduce the overall incidence of post-procedural acute kidney injury (AKI)5
- Reduce number of days in the hospital3,4
- Significantly reduce post-discharge MACCE events (composite of death/stroke/MI/repeat revascularization)6
![](https://d1edr79mp9g5zc.cloudfront.net/5eb0affe-1991-449b-bfc0-a5a0516548bf/b678c4b5-1b9d-47c4-ac56-457e39a49aee/b678c4b5-1b9d-47c4-ac56-457e39a49aee_source__v.jpg)
Surgical Turndown is Common and Associated with Higher Mortality
Protected PCI may be an option when surgery is not. Consider Protected PCI for patients who are considered too high-risk and therefore turned down for surgery, and for patients who decline surgical treatment.
![](https://d1edr79mp9g5zc.cloudfront.net/5eb0affe-1991-449b-bfc0-a5a0516548bf/90106ea5-2abd-45cc-b4c4-106a2fbe88d1/90106ea5-2abd-45cc-b4c4-106a2fbe88d1_source__v.png)
![](https://d1edr79mp9g5zc.cloudfront.net/5eb0affe-1991-449b-bfc0-a5a0516548bf/90106ea5-2abd-45cc-b4c4-106a2fbe88d1/90106ea5-2abd-45cc-b4c4-106a2fbe88d1_source__v.png)
Underdiagnosed & Undertreated
Many patients with severe, symptomatic CAD remain untreated or undertreated due to comorbidities, increased risk of AKI or hemodynamic compromise.
Resources from the Education Library
Resources
References
-
Burzotta, F., et al. (2019). J Interv Cardiol, 2019(5):1-10.
-
O’Neill, W.W., et al. (2012). Circulation, 126(14), 1717-1727.
-
Gregory, D., et al. (2013). Am Health Drug Benefits, 6(2), 88-99.
-
Maini, B., et al. (2014). Expert Rev Pharmacoecon Outcomes Res, 14(3), 403-416.
- Flaherty, M.P., et al. (2017). Circ Res, 120(4), 692-700.
-
Dangas, G.D., et al. (2014). Am J Cardiol, 113(2), 222-228.
NPS-1180